- Home
- BRTX vs BCTX Comparison
BRTX vs BCTX Comparison
Compare BRTX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- BCTX
- Stock Information
- Founded
- BRTX 1997
- BCTX 2014
- Country
- BRTX United States
- BCTX Canada
- Employees
- BRTX N/A
- BCTX N/A
- Industry
- BRTX Managed Health Care
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- BCTX Health Care
- Exchange
- BRTX Nasdaq
- BCTX Nasdaq
- Market Cap
- BRTX 12.5M
- BCTX 14.2M
- IPO Year
- BRTX N/A
- BCTX N/A
- Fundamental
- Price
- BRTX $1.43
- BCTX $8.64
- Analyst Decision
- BRTX
- BCTX Strong Buy
- Analyst Count
- BRTX 0
- BCTX 1
- Target Price
- BRTX N/A
- BCTX $40.00
- AVG Volume (30 Days)
- BRTX 102.2K
- BCTX 84.7K
- Earning Date
- BRTX 11-11-2025
- BCTX 10-28-2025
- Dividend Yield
- BRTX N/A
- BCTX N/A
- EPS Growth
- BRTX N/A
- BCTX N/A
- EPS
- BRTX N/A
- BCTX N/A
- Revenue
- BRTX $605,200.00
- BCTX N/A
- Revenue This Year
- BRTX $232.67
- BCTX N/A
- Revenue Next Year
- BRTX $52.92
- BCTX N/A
- P/E Ratio
- BRTX N/A
- BCTX N/A
- Revenue Growth
- BRTX 247.62
- BCTX N/A
- 52 Week Low
- BRTX $1.21
- BCTX $6.00
- 52 Week High
- BRTX $2.55
- BCTX $214.50
- Technical
- Relative Strength Index (RSI)
- BRTX 37.54
- BCTX 51.22
- Support Level
- BRTX $1.56
- BCTX $7.93
- Resistance Level
- BRTX $1.63
- BCTX $8.20
- Average True Range (ATR)
- BRTX 0.10
- BCTX 0.48
- MACD
- BRTX -0.02
- BCTX 0.33
- Stochastic Oscillator
- BRTX 0.00
- BCTX 66.34
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.